Symptoms of overdose include bradycardia, cardiac failure, hypotension, and brochospasm.
Bupranolol is a non-selective beta blocker with potency similar to propanolol. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ceritinib | Bupranolol may increase the bradycardic activities of Ceritinib. |
| Ivabradine | Bupranolol may increase the bradycardic activities of Ivabradine. |
| Ruxolitinib | Ruxolitinib may increase the bradycardic activities of Bupranolol. |
| Alfuzosin | Alfuzosin may increase the hypotensive activities of Bupranolol. |
| Amifostine | Bupranolol may increase the hypotensive activities of Amifostine. |
| Diazoxide | Diazoxide may increase the hypotensive activities of Bupranolol. |
| Methylphenidate | Methylphenidate may decrease the antihypertensive activities of Bupranolol. |
| Dexmethylphenidate | Dexmethylphenidate may decrease the antihypertensive activities of Bupranolol. |
| Obinutuzumab | Bupranolol may increase the hypotensive activities of Obinutuzumab. |
| Pentoxifylline | Pentoxifylline may increase the hypotensive activities of Bupranolol. |
| Rituximab | Bupranolol may increase the hypotensive activities of Rituximab. |
| Desmopressin | Desmopressin may decrease the antihypertensive activities of Bupranolol. |
| Zolmitriptan | Zolmitriptan may decrease the antihypertensive activities of Bupranolol. |
| Doxapram | Doxapram may decrease the antihypertensive activities of Bupranolol. |
| Sumatriptan | Sumatriptan may decrease the antihypertensive activities of Bupranolol. |
| Phenmetrazine | Phenmetrazine may decrease the antihypertensive activities of Bupranolol. |
| Naratriptan | Naratriptan may decrease the antihypertensive activities of Bupranolol. |
| Rizatriptan | Rizatriptan may decrease the antihypertensive activities of Bupranolol. |
| Dopamine | Dopamine may decrease the antihypertensive activities of Bupranolol. |
| Frovatriptan | Frovatriptan may decrease the antihypertensive activities of Bupranolol. |
| Dutasteride | Dutasteride may decrease the antihypertensive activities of Bupranolol. |
| Finasteride | Finasteride may decrease the antihypertensive activities of Bupranolol. |
| Yohimbine | Yohimbine may decrease the antihypertensive activities of Bupranolol. |
| Epicaptopril | Epicaptopril may decrease the antihypertensive activities of Bupranolol. |
| 1-benzylimidazole | 1-benzylimidazole may decrease the antihypertensive activities of Bupranolol. |
| Amineptine | Amineptine may decrease the antihypertensive activities of Bupranolol. |
| Flibanserin | Flibanserin may decrease the antihypertensive activities of Bupranolol. |
| Naluzotan | Naluzotan may decrease the antihypertensive activities of Bupranolol. |
| Nitrous oxide | Nitrous oxide may decrease the antihypertensive activities of Bupranolol. |
| Cinitapride | Cinitapride may decrease the antihypertensive activities of Bupranolol. |
| Tyramine | Tyramine may decrease the antihypertensive activities of Bupranolol. |
| Ifenprodil | Ifenprodil may decrease the antihypertensive activities of Bupranolol. |
| Dimetacrine | Dimetacrine may decrease the antihypertensive activities of Bupranolol. |
| Moxisylyte | Moxisylyte may decrease the antihypertensive activities of Bupranolol. |
| Tianeptine | Tianeptine may decrease the antihypertensive activities of Bupranolol. |
| Oxaprotiline | Oxaprotiline may decrease the antihypertensive activities of Bupranolol. |
| Atipamezole | Atipamezole may decrease the antihypertensive activities of Bupranolol. |
| Tetrahydrocannabivarin | Tetrahydrocannabivarin may decrease the antihypertensive activities of Bupranolol. |
| Piclozotan | Piclozotan may decrease the antihypertensive activities of Bupranolol. |
| Siponimod | Siponimod may decrease the antihypertensive activities of Bupranolol. |
| Idazoxan | Idazoxan may decrease the antihypertensive activities of Bupranolol. |
| Tramazoline | Tramazoline may decrease the antihypertensive activities of Bupranolol. |
| Amitriptylinoxide | Amitriptylinoxide may decrease the antihypertensive activities of Bupranolol. |
| Dibenzepin | Dibenzepin may decrease the antihypertensive activities of Bupranolol. |
| Quinupramine | Quinupramine may decrease the antihypertensive activities of Bupranolol. |
| Trichloroethylene | Trichloroethylene may decrease the antihypertensive activities of Bupranolol. |
| Fenozolone | Fenozolone may decrease the antihypertensive activities of Bupranolol. |
| Melitracen | Melitracen may decrease the antihypertensive activities of Bupranolol. |
| Lofepramine | Lofepramine may decrease the antihypertensive activities of Bupranolol. |
| Xenon | Xenon may decrease the antihypertensive activities of Bupranolol. |
| Iprindole | Iprindole may decrease the antihypertensive activities of Bupranolol. |
| Buflomedil | Buflomedil may decrease the antihypertensive activities of Bupranolol. |
| Diethyl ether | Diethyl ether may decrease the antihypertensive activities of Bupranolol. |
| Imipramine oxide | Imipramine oxide may decrease the antihypertensive activities of Bupranolol. |
| Mefenorex | Mefenorex may decrease the antihypertensive activities of Bupranolol. |
| 5-methoxy-N,N-dimethyltryptamine | 5-methoxy-N,N-dimethyltryptamine may decrease the antihypertensive activities of Bupranolol. |
| Quinoline Yellow WS | Quinoline Yellow WS may decrease the antihypertensive activities of Bupranolol. |
| Solriamfetol | Solriamfetol may decrease the antihypertensive activities of Bupranolol. |
| Sufentanil | Sufentanil may decrease the antihypertensive activities of Bupranolol. |
| Remifentanil | Remifentanil may decrease the antihypertensive activities of Bupranolol. |
| Halothane | Halothane may decrease the antihypertensive activities of Bupranolol. |
| Opipramol | Opipramol may decrease the antihypertensive activities of Bupranolol. |
| Selpercatinib | Selpercatinib may decrease the antihypertensive activities of Bupranolol. |
| Naxitamab | Naxitamab may decrease the antihypertensive activities of Bupranolol. |
| Cannabidiol | The metabolism of Bupranolol can be decreased when combined with Cannabidiol. |
| Amiodarone | The therapeutic efficacy of Bupranolol can be increased when used in combination with Amiodarone. |
| Bupivacaine | The serum concentration of Bupivacaine can be increased when it is combined with Bupranolol. |
| Dipyridamole | Dipyridamole may increase the bradycardic activities of Bupranolol. |
| Disopyramide | Disopyramide may increase the bradycardic activities of Bupranolol. |
| Dronedarone | Dronedarone may increase the bradycardic activities of Bupranolol. |
| Fingolimod | Bupranolol may increase the bradycardic activities of Fingolimod. |
| Floctafenine | The risk or severity of adverse effects can be increased when Bupranolol is combined with Floctafenine. |
| Mepivacaine | The serum concentration of Mepivacaine can be increased when it is combined with Bupranolol. |
| Methacholine | Bupranolol may increase the bronchoconstrictory activities of Methacholine. |
| Midodrine | The therapeutic efficacy of Midodrine can be decreased when used in combination with Bupranolol. |
| Nifedipine | The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Bupranolol. |
| Propafenone | The risk or severity of adverse effects can be increased when Propafenone is combined with Bupranolol. |
| Regorafenib | Regorafenib may increase the bradycardic activities of Bupranolol. |
| Reserpine | Reserpine may increase the hypotensive activities of Bupranolol. |
| Deserpidine | Deserpidine may increase the hypotensive activities of Bupranolol. |
| Guanethidine | Guanethidine may increase the hypotensive activities of Bupranolol. |
| Rivastigmine | Bupranolol may increase the bradycardic activities of Rivastigmine. |
| Mirabegron | The serum concentration of Bupranolol can be increased when it is combined with Mirabegron. |
| Molsidomine | Molsidomine may increase the hypotensive activities of Bupranolol. |
| Insulin argine | Bupranolol may increase the hypoglycemic activities of Insulin argine. |
| Remikiren | Remikiren may increase the hypotensive activities of Bupranolol. |
| Guanadrel | Guanadrel may increase the hypotensive activities of Bupranolol. |
| Bosentan | Bosentan may increase the hypotensive activities of Bupranolol. |
| Candoxatril | Candoxatril may increase the hypotensive activities of Bupranolol. |
| Metyrosine | Metyrosine may increase the hypotensive activities of Bupranolol. |
| Cryptenamine | Cryptenamine may increase the hypotensive activities of Bupranolol. |
| Dorzolamide | Dorzolamide may increase the hypotensive activities of Bupranolol. |
| Bimatoprost | Bimatoprost may increase the hypotensive activities of Bupranolol. |
| Pentolinium | Pentolinium may increase the hypotensive activities of Bupranolol. |
| Trimethaphan | Trimethaphan may increase the hypotensive activities of Bupranolol. |
| Tienilic acid | Tienilic acid may increase the hypotensive activities of Bupranolol. |
| Debrisoquine | Debrisoquine may increase the hypotensive activities of Bupranolol. |
| Sitaxentan | Sitaxentan may increase the hypotensive activities of Bupranolol. |
| Ambrisentan | Ambrisentan may increase the hypotensive activities of Bupranolol. |
| Diethylnorspermine | Diethylnorspermine may increase the hypotensive activities of Bupranolol. |